Business Description
Cocrystal Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US19188J3005
Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.22 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.1 | |||||
| 3-Year EPS without NRI Growth Rate | -1.7 | |||||
| 3-Year FCF Growth Rate | 11.2 | |||||
| 3-Year Book Growth Rate | -33.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.17 | |||||
| 9-Day RSI | 52.56 | |||||
| 14-Day RSI | 52.18 | |||||
| 6-1 Month Momentum % | -14.29 | |||||
| 12-1 Month Momentum % | -41.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.92 | |||||
| Quick Ratio | 8.92 | |||||
| Cash Ratio | 8.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.1 | |||||
| Shareholder Yield % | -1.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -54.17 | |||||
| ROA % | -50.28 | |||||
| ROIC % | -1031.84 | |||||
| ROC (Joel Greenblatt) % | -1685.74 | |||||
| ROCE % | -63.32 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 0.6 | |||||
| EV-to-EBIT | 0.41 | |||||
| EV-to-EBITDA | 0.41 | |||||
| EV-to-FCF | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 0.65 | |||||
| Price-to-Net-Cash | 0.74 | |||||
| Earnings Yield (Greenblatt) % | 243.9 | |||||
| FCF Yield % | -93.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cocrystal Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.763 | ||
| Beta | 0.79 | ||
| Volatility % | 54.01 | ||
| 14-Day RSI | 52.18 | ||
| 14-Day ATR (€) | 0.039848 | ||
| 20-Day SMA (€) | 1.367 | ||
| 12-1 Month Momentum % | -41.07 | ||
| 52-Week Range (€) | 1.24 - 2.82 | ||
| Shares Outstanding (Mil) | 10.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cocrystal Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cocrystal Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cocrystal Pharma Inc Frequently Asked Questions
What is Cocrystal Pharma Inc(STU:8CC)'s stock price today?
The current price of STU:8CC is €1.38. The 52 week high of STU:8CC is €2.82 and 52 week low is €1.24.
When is next earnings date of Cocrystal Pharma Inc(STU:8CC)?
The next earnings date of Cocrystal Pharma Inc(STU:8CC) is 2024-05-15 Est..
Does Cocrystal Pharma Inc(STU:8CC) pay dividends? If so, how much?
Cocrystal Pharma Inc(STU:8CC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers